A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels

Phase 4 Completed 60 enrolled Novartis Genentech, Inc. · collab Tanox · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This study was intended to demonstrate that patients with standard and high immunoglobulin E (IgE) levels can be protected from allergen induced broncho-constriction by Xolair

Timeline

Start: 2008-02
Primary completion: 2009-01
Completion: 2009-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omalizumab	Monoclonal antibody	450 mg	Subcutaneous
Subject	Omalizumab	Monoclonal antibody	525 mg	Subcutaneous
Subject	Omalizumab	Monoclonal antibody	600 mg	Subcutaneous

A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels

Summary

Timeline

Drugs

Indications